References

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

10.1016/j.annonc.2023.11.015 · 2024 · External reference

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2023.07.011 · 2023 · External reference

Niraparib in patients with newly diagnosed advanced ovarian cancer

10.1056/nejmoa1910962 · 2019 · External reference

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

10.1016/j.annonc.2024.08.2241 · 2024 · External reference

Unresolved reference

2025 · External reference

Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase III randomized clinical trial

10.1001/jamaoncol.2023.2283 · 2023 · External reference

Niraparib as first-line maintenance therapy in patients with stage III ovarian cancer and no visible residual disease: AR1ZE real-world study

10.1007/s40487-024-00318-y · 2025 · External reference

A phase III trial of bevacizumab in ovarian cancer

10.1056/nejmoa1103799 · 2011 · External reference

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

10.1016/j.ygyno.2021.12.016 · 2022 · External reference

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

10.1136/ijgc-2023-004995 · 2024 · External reference